Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
53 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
AXONE PHARMA from Braine-l'Alleud, company number BE0830551216, closed financial year 2025 with a result of € 1.6 million after tax. For that financial year AXONE PHARMA recorded revenue of € 27.1 million and equity of € 8.1 million. Compared with financial year 2024, the result moved from € 695,941 to € 1.6 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 8.1 million
▲ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.6 million
▲ 132% vs 2024
Profit after tax over the fiscal year.
€ 2.7 million
▲ 132% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 7.8 million.
People and assets in 2025
28.2
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.4 million
▲ 9% vs 2024
€ 83,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 43,450
▲ 13% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4.7 million
▲ 138% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 78 days on average.
€ 532,674
▲ 15% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 13,822,607 | € 13,943,302 | € 14,546,329 | € 27,080,922 | ▲ 86% |
| Profit after taxes | € 682,151 | € 557,175 | € 695,941 | € 1,611,272 | ▲ 132% |
| Equity | € 8,713,395 | € 5,770,570 | € 6,466,511 | € 8,077,783 | ▲ 25% |
| Total debts | € 1,400,839 | € 2,892,952 | € 2,734,343 | € 8,118,359 | ▲ 197% |
| Cash | € 337,268 | € 300,000 | € 1,187,391 | € 2,749,708 | ▲ 132% |
| Retained profit | € 8,413,395 | € 5,470,570 | € 6,166,511 | € 7,777,783 | ▲ 26% |
| Dividend | € 0 | € 3,500,000 | € 0 | € 0 | |
| Balance sheet total | € 10,114,234 | € 8,663,522 | € 9,200,854 | € 16,230,903 | ▲ 76% |
| Employees (FTE) | 30.5 | 30.1 | 28.1 | 28.2 | ▲ 0.1 |
Key figures of AXONE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AXONE PHARMA?
What happened at AXONE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.6 million (▲ 132% vs 2024). Source: NBB ↗
- New establishment in Braine-l'Alleud. KBO
- New establishment in Braine-l'Alleud. KBO
- Start of the company according to the CBE. KBO
In short
From € 682,151 profit in 2022 to € 1.6 million profit in 2025.
Paid € 1.6 million in corporate taxes since 2022.
Best year ever: 2025, with € 1.6 million profit.
Paid out € 3.5 million in dividends to the owners in total.
A new publication or filing at AXONE PHARMA? We notify you, reason included.
Follow AXONE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of FEBELCO, FEBELFARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
AXONE PHARMABehind AXONE PHARMA are Suru Consult and Alexo. The shares are held by FEBELCO (99.9%) and FEBELFARMA (0.1%).
Directors
According to the 2025 annual accounts
Managing director · represented by Ruben Suply
Director · represented by Olivier Delaere
Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more
Shareholders
99.9%
0.1%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Boulevard de France 9 box A
1420 Braine-l'Alleud
Avenue de Finlande 8
1420 Braine-l'Alleud
Active since 1 January 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 53 companies are registered at this address.
All companies at this address →MERIDIAN BIOSCIENCE EUROPE
€ 406,506 gross margin · 2025
ODYSSEY FINANCIAL TECHNOLOGIES
€ 963,129 gross margin · 2025
SET SEVEN
€ -41,144 gross margin · 2025
TAXI BERNARD DUBOIS
€ 3,463 gross margin · 2025
Elite Limousine Service
€ 88,566 gross margin · 2024
+48 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0830.551.216
- VAT number
- BE 0830.551.216
- Registered office
- Boulevard de France 9 bus A, 1420 Braine-l'Alleud
- Names & denominations
- AXONE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 October 2010
- Peppol
- Active · Active since 17 Sept 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in andere specifieke goederen